At Janssen Asia Pacific, we are more than 7,000 people, including doctors, scientists, engineers, quality and policy experts, business leaders and commercial people, working together across the region to improve people’s health. We operate research and development (R&D) and manufacturing sites and are part of a worldwide organization that is the seventh largest pharmaceutical company in the world. We research and develop prescription medicines for some of the world’s most serious and prevalent diseases, ranging from cancer and rheumatoid arthritis, to life-threatening bacterial infections and HIV/AIDS.
But, most importantly, we are like you: individuals with personal passions and commitments. Like you, we have parents to look after, children to care for, and friends and family to support. And, for people like them and everyone, we want to bring meaningful solutions to this world.
We believe in doing what’s right. We are honored to work with doctors, researchers, patient groups and policy makers. We work within and beyond our communities, with the goal of improving our interconnected world and always acting on behalf of patients to improve care.
Contact
Janssen, a division of Johnson & Johnson Pte Ltd
2, International business Park
#07-01, Tower One
The Strategy
Singapore 609930
T: +65 6705 6895
J&J India’s Jayashri Kulkarni lays out her approach to comprehensive leadership, drawing on her diverse career history across various sectors; her mandate to leverage innovative assets to transform disease management…
Portugal boasts a well-developed universal healthcare system and saw healthcare spending increase by 6.2 percent annually between 2016 and 2021, according to the OECD. However, the representatives of innovative medicines…
Speaking to PharmaBoardroom as Janseen is rebranding as Johnson & Johnson Innovative Medicine, managing director for Portugal, Filipa Mota e Costa, discusses the affiliate’s expanded local footprint and its ranking…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover…
Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off…
Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux…
After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that…
A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s…
Christian Rodseth, VP and managing director for Janssen’s Greece, Poland, and Romania cluster, outlines the multifaceted strengths of his teams, the part of the Janssen portfolio he is most excited…
China’s strict ‘dynamic COVID-zero’ policy, relying on lockdowns, mass-testing and border controls to stamp out COVID-19 outbreaks wherever they appear, has undoubtedly constricted the country’s economic growth and prompted uncommon…
Through compassionate use programs patients suffering from critical, life-threatening conditions can access potential life-saving therapeutic options which have not been formally approved by the responsible health authority in an ethical…
See our Cookie Privacy Policy Here
